GLP-1 Weight Loss for All of New Jersey: North, Central, and South Jersey Coverage
Published by New Jersey Trim Clinic · Updated 2025-03-14
Statewide GLP-1 Medical Weight Loss for New Jersey
New Jersey Trim Clinic serves adults across the entire state of New Jersey through our telehealth platform. Whether you are in North Jersey, Central Jersey, South Jersey, or along the Shore, our physician-supervised GLP-1 programs are accessible from your home.
North Jersey
North Jersey residents from Bergen County to Morris County to Essex County can access our telehealth GLP-1 programs. Communities we serve include Hackensack, Paramus, Fort Lee, Jersey City, Hoboken, Newark, Elizabeth, Paterson, and Morristown, among many others.
For North Jersey professionals who commute into New York City, our telehealth model means you can schedule appointments around your work schedule — no taking time off for an office visit. Your consultation, follow-ups, and ongoing care happen through secure video.
Central Jersey
Yes, Central Jersey exists — and we serve it. From Middlesex County to Somerset County to Mercer County, Central Jersey residents can access our physician-supervised semaglutide and tirzepatide programs via telehealth.
Communities including New Brunswick, Edison, Somerset, Princeton, and Trenton are all within our service area. Central Jersey's suburban communities benefit from telehealth by eliminating the need to drive to a specialist's office.
South Jersey
South Jersey residents from Camden County to Atlantic County to Cape May County can access our GLP-1 programs from home. We serve Cherry Hill, Camden, Somers Point, Atlantic City, Ocean City, Egg Harbor, Cape May, and Burlington County communities.
For South Jersey patients who may have limited local access to medical weight loss specialists, our telehealth model bridges that gap by connecting you with experienced providers.
The Jersey Shore
Shore communities from Sandy Hook to Cape May Point are served through our telehealth platform. Whether you are a year-round resident or seasonal, our programs are accessible from wherever you are in New Jersey.
How It Works Statewide
Regardless of where you live in New Jersey, the process is the same. You schedule a free initial consultation through our telehealth platform. A licensed medical provider evaluates your health and determines if GLP-1 medication is appropriate. If prescribed, medication is sourced from licensed U.S. pharmacies and shipped to your home. Regular telehealth check-ins provide ongoing physician oversight.
Pricing
Programs start at $149 per month, all-inclusive, with no membership fees or hidden costs. The same pricing and level of care applies whether you are in Bergen County or Cape May. Individual results vary and no specific weight loss is guaranteed.
New Jersey Trim Clinic provides experienced telehealth medical weight loss care to adults across all of New Jersey.
MEDICAL SOURCES & FURTHER READING
Read the source alongside the specific topic it supports. These independent sources do not endorse New Jersey Trim Clinic. Research findings are not a prediction of your results.
- NIH/NIDDK — Prescription Medications to Treat Overweight & Obesity
Supports: Weight-management medication requires individualized prescribing; eligibility, benefits, risks and ongoing treatment should be discussed with a healthcare professional. Nutrition and physical activity remain part of treatment.
- Mayo Clinic — Prescription weight-loss drugs
Supports: Prescription weight-loss medicines have eligibility restrictions, potential side effects and a need for professional oversight; they are used alongside lifestyle measures.
- Cleveland Clinic — GLP-1 Agonists
Supports: GLP-1 receptor agonists act on appetite and satiety, help regulate blood glucose and can slow stomach emptying. Common adverse effects include nausea, vomiting and diarrhea.
Evidence limits: The extent and duration of effects differ by drug, dose and individual; a general mechanism does not establish a guaranteed response.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
Supports: Semaglutide 2.4 mg plus lifestyle intervention produced weight loss in the STEP 1 randomized trial; gastrointestinal adverse events were reported.
Evidence limits: The main trial reported mean weight change of −14.9% at 68 weeks. This is not a predicted clinic outcome or proof that every semaglutide formulation has the same results.
- FDA — Wegovy (semaglutide) prescribing information
Supports: The approved product's label describes contraindications including personal or family history of medullary thyroid carcinoma and MEN 2, dose escalation, pregnancy considerations, gastrointestinal reactions, and warnings including pancreatitis, gallbladder disease and kidney injury due to volume depletion.
Evidence limits: This label is for Wegovy, not approval of New Jersey Trim Clinic or a compounded formulation. Individual prescribing decisions require a licensed provider.
- Tirzepatide Once Weekly for the Treatment of Obesity
Supports: The SURMOUNT-1 trial studied tirzepatide at different doses in adults with obesity or overweight without diabetes and reported weight reduction and gastrointestinal adverse events.
Evidence limits: SURMOUNT-1 was placebo-controlled, not a head-to-head comparison with semaglutide. Results do not establish guaranteed outcomes or equivalence of compounded medicines.
- FDA — Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
Supports: Compounded GLP-1 drugs are not FDA-approved. FDA describes dosing, quality, storage and other safety concerns, and advises that compounded drugs should only be used when a patient's medical needs cannot be met by an FDA-approved drug.
Evidence limits: Pharmacy registration is not FDA approval of a compounded product. Clinical trials of approved drugs do not establish the safety or effectiveness of compounded formulations.
RESEARCH & REFERENCES
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding JPH, Batterham RL, Calanna S, et al.; STEP 1 Study Group. New England Journal of Medicine. 2021.
Research published in the New England Journal of Medicine reported greater weight reduction with semaglutide 2.4 mg plus lifestyle intervention than placebo in the studied adults without diabetes.
- Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff AM, Aronne LJ, Ahmad NN, et al.; SURMOUNT-1 Investigators. New England Journal of Medicine. 2022.
Research published in the New England Journal of Medicine reported dose-dependent weight reduction with tirzepatide versus placebo over 72 weeks in the studied population.
General education is not individualized medical advice. Prescription treatment requires evaluation by a licensed provider. Eligibility, medication and dosing depend on individual circumstances.
Compounded drugs are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness or quality before marketing. Compounded drugs should only be used when a patient's medical needs cannot be met by an FDA-approved drug. Published studies of approved medications do not establish equivalent safety or effectiveness of compounded products.